The United Kingdom and the United States have forged a important bilateral deal that will ensure zero duties on British pharmaceutical shipments being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase spending on pharmaceuticals through the public health system. This pledge guarantees that duties on these vital exports will be held at nothing for a timeframe of three years.
This development is in response to earlier threats to hike import taxes on branded drug products, with increases discussed as high as double the cost.
"This deal with the UK reinforces the global environment for cutting-edge drugs and introduces much-needed equity to American-British drug exports," a statement declared.
Trade Importance
Medicines constitute one of the Britain's most significant export categories to the America, which is by far the largest destination for major British pharmaceutical firms.
Trade data show that in the one-year period leading up to last September, the UK exported pharmaceutical products valued at £11.1bn to the US. This amount represented 17.4% of all goods exports in that timeframe.
"This guarantee secures jobs, boosts capital expenditure and facilitates the UK to become a international leader for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The pact includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to increase total public funding on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to stay within budget will be limited at 15%. Previously, refunds exceeded 20%.
Recent Tensions
The deal follows a protracted row between the sector and the UK government over medicine costs and regulatory access.
This friction were intensified by assertions that American consumers were charged several times more for the equivalent treatments than consumers in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been paused or abandoned, while major expansions have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
